Creating a questionnaire to assess abdominal issues in cystic fibrosis patients
Official title: Evaluation and Validation of a New Questionnaire to Identify and Quantify Abdominal Symptoms in Patients With Cystic Fibrosis Following FDA Guidelines: the CF Abd-Score (Primarily Named JenAbdomen-CF Score)
Run by Medizinische Hochschule Brandenburg Theodor Fontane · NCT03052283 · Data updated 2026-11-12
This study is trying to create a new questionnaire to help cystic fibrosis patients report their abdominal issues so that doctors can better understand and treat them.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | Medizinische Hochschule Brandenburg Theodor Fontane Academic / other |
| Locations | 2 sites (Brandenburg an der Havel and 1 other locations) |
| Status | Recruiting |
| Started | January 26, 2017 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | April 4, 2023 |
| Trial ID | NCT03052283 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with cystic fibrosis and age-matched healthy controls.
✕Probably not a fit
Patients with other diseases causing abdominal symptoms, such as inflammatory bowel disease or celiac disease, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on developing and validating a new patient-reported outcome measure (PROM) specifically designed to assess abdominal involvement in individuals with cystic fibrosis (CF). The CFAbd-Score will be created through a collaborative process involving CF patients, their families, and healthcare professionals. The study will evaluate the reliability, reproducibility, and responsiveness of the questionnaire, as well as its applicability across different age groups and CF centers. Additionally, the study aims to adapt the CFAbd-Score for use in various countries and languages.
Why it matters
Potential benefit: If successful, this study could provide a standardized tool for better monitoring and management of abdominal symptoms in cystic fibrosis patients.
How similar studies have gone: Other studies have successfully developed disease-specific PROMs, indicating a promising approach for this novel tool.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: CF cohort: Diagnosis of CF determined by * a sweat chloride of \>60 mEq/L and/or * detection of 2 disease causing CFTR mutations with evidence of organ involvement. Healthy controls: * Age-matched Exclusion Criteria: CF cohort: * Lacking ability to cooperate of patients /their families, respectively Healthy controls: * Other diseases causing abdominal symptoms (Inflammatory bowel disease (IBD), alpha 1 antitrypsin deficiency, celiac disease, food allergy, gastroenteritis, etc.)
Where it's running
-
Klinikum Westbrandenburg
Brandenburg an der Havel, Germany Recruiting -
Medizinische Hochschule Brandenburg (MHB), University
Brandenburg an der Havel, Germany Recruiting
Study contacts
- Principal investigator: Jochen G Mainz, Prof. MD — Medizinische Hochschule Brandenburg (MHB), University
- Study coordinator: Jochen G Mainz, Prof. MD
- Email: jochen.mainz@mhb-fontane.de
- Phone: +493381411803
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Inhaled CFTR mRNA for cystic fibrosis in Chinese patients aged 12 and older
This trial tests inhaled BMD003, a CFTR mRNA therapy, to see if it's safe and shows early signs of benefit in Chinese people 12 years and up with cystic fibrosis.
-
VX-272 dose escalation in healthy adults
This will test single and multiple increasing doses of the experimental drug VX-272 in healthy adults to see how safe it is and how the body handles it.
-
Prevalence of smoking, passive smoke exposure, and vaping among adults with cystic fibrosis
This project will see how common smoking, exposure to secondhand smoke, and vaping are among adults with cystic fibrosis followed at the Strasbourg Adult CF Center.
-
Dose escalation of VX-581 to check safety and drug levels in healthy adults
The trial will test increasing doses of VX-581 in healthy adults to see if it is safe and to measure how the body absorbs and clears the drug.
-
PALMIRE cohort: phenotyping inflammatory lung diseases to enable personalized care
This project will collect clinical, imaging, and biological data from adults with asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung disease to try to identify disease subtypes and markers that could guide more personalized care.
-
Collecting sputum samples at home for cystic fibrosis patients
This study is testing if collecting sputum samples at home can help people with cystic fibrosis better identify lung infections compared to traditional methods done at the clinic.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.